Cargando…

Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer

Given the heterogeneity of solid tumors, single-target CAR-T cell therapy often leads to recurrence, especially in ovarian cancer (OV). Here, we constructed a Tandem-CAR targeting two antigens with secretory activity (IL-12) to improve the effects of CAR-T cell therapy. Twenty coexpressed upregulate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Zhen, Dong, Jiao, Yang, Neng, Li, Si-Di, Yang, Ze-Yu, Huang, Rui, Li, Feng-Jie, Wang, Wen-Ting, Ren, Jia-Kui, Lei, Jie, Xu, Chen, Wang, Dan, Wang, Yan-Zhou, Liang, Zhi-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579462/ https://www.ncbi.nlm.nih.gov/pubmed/34803504 http://dx.doi.org/10.7150/ijbs.63181

Ejemplares similares

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
por: Schoutrop, Esther, et al.
Publicado: (2023)

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells
por: Huang, Ming-ju, et al.
Publicado: (2018)

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
por: Schoutrop, Esther, et al.
Publicado: (2022)

Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling
por: Yang, Xu, et al.
Publicado: (2021)

MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer
por: Li, Yike, et al.
Publicado: (2022)

Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer
por: Kim, Minsung, et al.
Publicado: (2018)

HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
por: Tegeler, Christian M., et al.
Publicado: (2022)

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer
por: Deng, Li, et al.
Publicado: (2012)

Effects of hsa-mir-145-5p on the Regulation of msln Expression in Colorectal Adenocarcinoma
por: Li, Junhua, et al.
Publicado: (2022)

Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate
por: Tang, Thao, et al.
Publicado: (2022)

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target
por: Le, Quy, et al.
Publicado: (2022)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy
por: Zeng, Wuyi, et al.
Publicado: (2022)

Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
por: Goricar, Katja, et al.
Publicado: (2020)

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Differentially expressed genes in embryonic cardiac tissues of mice lacking Folr1 gene activity
por: Zhu, Huiping, et al.
Publicado: (2007)

Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
por: Köbel, M, et al.
Publicado: (2014)

Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism
por: Yang, Quanjun, et al.
Publicado: (2022)

A promising antitumor method: Targeting CSC with immune cells modified with CAR
por: Huang, Binjie, et al.
Publicado: (2022)

Site-specific glycoproteomic analysis revealing increased core-fucosylation on FOLR1 enhances folate uptake capacity of HCC cells to promote EMT
por: Jia, Li, et al.
Publicado: (2021)

Reinforcing one-carbon metabolism via folic acid/Folr1 promotes β-cell differentiation
por: Karampelias, Christos, et al.
Publicado: (2021)

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
por: Zhao, Songbo, et al.
Publicado: (2021)

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer
por: Zhao, Ruocong, et al.
Publicado: (2021)

CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

FolR1: a novel cell surface marker for isolating midbrain dopamine neural progenitors and nascent dopamine neurons
por: Gennet, Nicole, et al.
Publicado: (2016)

CIC de novo loss of function variants contribute to cerebral folate deficiency by downregulating FOLR1 expression
por: Cao, Xuanye, et al.
Publicado: (2021)

FOLR1-induced folate deficiency reduces viral replication via modulating APOBEC3 family expression
por: Wu, Jing, et al.
Publicado: (2023)

High Expression of Folate Receptor Alpha (FOLR1) is Associated With Aggressive Tumor Behavior, Poor Response to Chemoradiotherapy, and Worse Survival in Rectal Cancer
por: Chen, Chih-I, et al.
Publicado: (2022)

Single-cell profiling reveals the trajectory of FOLR2-expressing tumor-associated macrophages to regulatory T cells in the progression of lung adenocarcinoma
por: Xiang, Chan, et al.
Publicado: (2023)

TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
por: Nai, Yaru, et al.
Publicado: (2021)

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014)

Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma
por: Takihata, Yasuhiro, et al.
Publicado: (2021)

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence
por: Hu, Qian, et al.
Publicado: (2021)

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers
por: Notaro, Sara, et al.
Publicado: (2016)

Folic acid modifies the shape of epithelial cells during morphogenesis via a Folr1 and MLCK dependent mechanism
por: Martin, Jessica B., et al.
Publicado: (2019)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
por: Liao, Chan, et al.
Publicado: (2023)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qssf7sqdvaoqqrsop0plr1diub